-+ 0.00%
-+ 0.00%
-+ 0.00%

Janux Therapeutics Initiates Phase 1b Expansion Studies In Ongoing ENGAGER-PSMA-01 Trial

Benzinga·05/05/2025 12:37:36
Listen to the news
  • Phase 1b expansion study initiated in taxane-naïve mCRPC patients
  • Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion
  • Updates on JANX007 and JANX008 expected in the second half of 2025
  • Janux to host R&D Day in mid-2025 highlighting preclinical pipeline progression to the clinic

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA-01 trial.